Climb Bio, Inc.

CLYM · Nasdaq · United States

Share price · CLYM

$9.30-8.09 (-46.52%) 3M

close as of 2026-11-18 · 24h delayed · vol 865K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CLYM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+16.0%
  2. 26 Oct 2026-13.5%
  3. 26 Aug 2026-9.9%
  4. 14 Aug 2026+10.9%
  5. 6 Aug 2026+12.3%
  6. 1 Jun 2026+7.7%
  7. 5 May 2026+18.2%
  8. 9 Apr 2026+13.4%

    Nothing announced by CLYM that day or the session before.

  9. 16 Dec 2025+21.3%
  10. 15 Dec 2025+27.0%

    Nothing announced by CLYM that day or the session before.

Share of unusual movement by asset

For each asset, the share of CLYM's own-move activity since 27 Sep 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
budoprutug
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—20%
Sessions with no dated event—76%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
CD19Monoclonal antibody
Systemic Lupus ErythematosusPrimary Membranous Nephropathy

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
August 2027 (1)
budoprutugPhase 1/2Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19
Est. primary completion 2027-08 · NCT07043946 · CT.gov ↗
What to watch
September 2027 (1)
budoprutugPhase 1/2Systemic Lupus Erthematosus
Est. primary completion 2027-09 · NCT07564596 · CT.gov ↗
What to watch
October 2027 (1)
budoprutugPhase 2Primary Membranous Nephropathy
Est. primary completion 2027-10 · NCT07096843 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 October 2026Topline resultbudoprutugInitial PrisMN Phase 2 data (interim): mean PLA2R antibody reduction 70% at Week 12; 5 of 13 in immunologic remission
US · Climb Bio, Inc. · Source ↗
5 May 2026Topline resultbudoprutugPhase 1 topline of subcutaneous budoprutug in healthy volunteers
Climb Bio, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$11M$40M+ $166M short-term inv.$15M-$12M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$9.7M$44M+ $139M short-term inv.$14M-$11M operating cash flowreport ↗
2026-Q1—$9.4M$8.4M+ $101M short-term inv.$14M-$14M operating cash flowreport ↗
2025-Q3—$9.1M$26M+ $61M short-term inv.$13M-$12M operating cash flowreport ↗
2025-Q2—$6.6M$23M+ $62M short-term inv.$8.7M-$11M operating cash flowreport ↗
2025-Q1—$17M$29M+ $69M short-term inv.$21M-$15M operating cash flowreport ↗
2024-Q3—$6.1M$146M+ $47M short-term inv.$8.9M-$7.5M operating cash flowreport ↗
2024-Q2—$1.1M$223M+ $0 short-term inv.$55M-$0.7M operating cash flowreport ↗
2024-Q1—$1.1M$105M+ $0 short-term inv.$1.7M-$1.8M operating cash flowreport ↗
2023-Q3—$2.9M$57M+ $50M short-term inv.$4.0M$3.5M operating cash flowreport ↗
2023-Q2—$3.7M$25M+ $77M short-term inv.$5.2M-$8.0M operating cash flowreport ↗
2023-Q1—$5.7M$34M+ $75M short-term inv.$22M-$15M operating cash flowreport ↗
2022-Q3—$4.3M$36M+ $87M short-term inv.$9.7M-$4.2M operating cash flowreport ↗
2022-Q2—$8.7M$33M+ $90M short-term inv.$15M-$14M operating cash flowreport ↗
2022-Q1—$8.1M$32M+ $92M short-term inv.$13M-$11M operating cash flowreport ↗
2021-Q3—$5.7M$63M+ $83M short-term inv.$9.6M-$13M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$47M$36M+ $65M short-term inv.$15M-$54M operating cash flowreport ↗

Climb Bio reported full-year 2025 results with no revenue disclosed. R&D spend was $46.71M, up 229.4% YoY from $14.18M, and cash, cash equivalents, and marketable securities totaled $160.7M as of December 31, 2025. The company recorded a net loss of $59.85M for the year.

Management guided that cash is expected to fund operations into 2028. Dosing completed in the Phase 1 study of the budoprutug subcutaneous formulation, with data expected in H1 2026; budoprutug trials in pMN, ITP, and SLE are ongoing, with initial data expected in H2 2026. Enrollment continues in the CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026, and a China SLE study is expected to dose its first patient in H1 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$14M$87M+ $64M short-term inv.$18M-$16M operating cash flowreport ↗
2023-FY—$15M$93M+ $14M short-term inv.$8.8M-$21M operating cash flowreport ↗
2022-FY—$26M$44M+ $80M short-term inv.$11M-$37M operating cash flowreport ↗
2021-FY—$22M$47M+ $90M short-term inv.$12M-$36M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($780K), 6 sales ($2.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-28RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% ownerOption exercise10,000$3.46$35KForm 4
2026-09-28RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% ownerOption exercise10,000$3.00$30KForm 4
2026-09-28RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% ownerOption exercise10,000$7.89$79KForm 4
2026-09-28RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% ownerOption exercise40,000$1.29$52KForm 4
2026-09-28RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% ownerOption exercise (derivative)10,000——Form 4
2026-09-28RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% ownerOption exercise (derivative)10,000——Form 4
2026-09-28RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% ownerOption exercise (derivative)10,000——Form 4
2026-09-28RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% ownerOption exercise (derivative)40,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 80 reporting institutions held 32.3M shares ($207.8M, 55.0% of shares outstanding).

#InstitutionSharesValue
1RA CAPITAL MANAGEMENT, L.P.11,300,939$77.4M
2MPM BIOIMPACT LLC2,593,439$17.8M
3BRAIDWELL LP1,529,675$10.5M
4GREAT POINT PARTNERS LLC1,334,130$9.1M
5MILLENNIUM MANAGEMENT LLC1,276,260$8.7M
6VANGUARD CAPITAL MANAGEMENT LLC1,178,659$8.1M
7Kynam Capital Management, LP1,003,341$6.9M
8MARSHALL WACE, LLP773,123$5.3M
9Affinity Asset Advisors, LLC700,000$4.8M
10SILVERARC CAPITAL MANAGEMENT, LLC684,908$4.7M
11Driehaus Capital Management LLC600,946$4.1M
12ADAR1 Capital Management, LLC597,662$4.1M
13NAN FUNG TRINITY (HK) LTD420,517$2.9M
14SPHERA FUNDS MANAGEMENT LTD.419,247$2.9M
15BlackRock, Inc.401,649$2.8M